These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1054 related articles for article (PubMed ID: 27127178)
1. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
2. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651 [TBL] [Abstract][Full Text] [Related]
3. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF Wang N; Wen J; Ren W; Wu Y; Deng C Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836 [TBL] [Abstract][Full Text] [Related]
4. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023 [TBL] [Abstract][Full Text] [Related]
5. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268 [TBL] [Abstract][Full Text] [Related]
6. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325 [TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442 [TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
10. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. Dadu R; Shah K; Busaidy NL; Waguespack SG; Habra MA; Ying AK; Hu MI; Bassett R; Jimenez C; Sherman SI; Cabanillas ME J Clin Endocrinol Metab; 2015 Jan; 100(1):E77-81. PubMed ID: 25353071 [TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
14. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146 [TBL] [Abstract][Full Text] [Related]